202 related articles for article (PubMed ID: 32737930)
1. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Kim HS; Kim H; Lee SH; Kim JH
J Clin Pharm Ther; 2020 Dec; 45(6):1264-1270. PubMed ID: 32737930
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Würzner G; Gerster JC; Chiolero A; Maillard M; Fallab-Stubi CL; Brunner HR; Burnier M
J Hypertens; 2001 Oct; 19(10):1855-60. PubMed ID: 11593107
[TBL] [Abstract][Full Text] [Related]
3. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
[TBL] [Abstract][Full Text] [Related]
4. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
Smink PA; Bakker SJ; Laverman GD; Berl T; Cooper ME; de Zeeuw D; Lambers Heerspink HJ
J Hypertens; 2012 May; 30(5):1022-8. PubMed ID: 22388234
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
6. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
7. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
[TBL] [Abstract][Full Text] [Related]
8. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
[TBL] [Abstract][Full Text] [Related]
10. Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care.
Hurwitz JT; Grizzle AJ; Augustine J; Rehfeld R; Wild A; Abraham I
J Manag Care Spec Pharm; 2016 Jan; 22(1):40-8. PubMed ID: 27015050
[TBL] [Abstract][Full Text] [Related]
11. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
13. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
14. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
15. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.
Bertero E; Miceli R; Lorenzoni A; Balbi M; Ghigliotti G; Chiarella F; Brunelli C; Viazzi F; Pontremoli R; Canepa M; Ameri P
Intern Emerg Med; 2019 Oct; 14(7):1083-1090. PubMed ID: 30835055
[TBL] [Abstract][Full Text] [Related]
16. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
18. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide.
Mamdani M; Gomes T; Greaves S; Manji S; Juurlink DN; Tadrous M; Kennedy SH; Antoniou T
JAMA Netw Open; 2019 Oct; 2(10):e1913304. PubMed ID: 31617924
[TBL] [Abstract][Full Text] [Related]
19. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
[TBL] [Abstract][Full Text] [Related]
20. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
Inoue A; Babazono T; Iwamoto Y
Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
